Table 3 |
||||
|
Relationship between CRP reduction and ACR response following ACZ885 treatment |
||||
| Group |
CRP reduction at day 43 versus baseline |
ACR response at day 43 |
||
|
|
||||
| <20% |
20% to <50% |
50% or more |
||
|
|
||||
| 10 mg/kg ACZ885 |
<20% |
4 |
0 |
0 |
| 20 to <50% |
0 |
1 |
1 |
|
| 50% or more |
8 |
2 |
2 |
|
| Placebo |
<20% |
9 |
1 |
0 |
| 20 – <50% |
2 |
0 |
0 |
|
| 50% or more |
3 |
0 |
0 |
|
|
|
||||
|
Relationship between C-reactive protein (CRP) reduction and American College of Rheumatology (ACR) response at day 43 for patients in the 10 mg/kg group and patients receiving placebo. Note that two subjects are excluded from the 10 mg/kg ACZ885 because of missing data. |
||||
|
Alten et al. Arthritis Research & Therapy 2008 10:R67 doi:10.1186/ar2438 |
||||
